RhumbLine Advisers
BLUE

RhumbLine Advisers’s bluebird bio BLUE Stock Holding History

RhumbLine Advisers’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,522
Closed -$61.1K – 4156
2025
Q1 		$61.1K Sell
12,522
-1,654
-12% -$9.95K ﹤0.01% 3531
2024
Q4 		$118K Buy
14,176
+621
+5% +$5.43K ﹤0.01% 3427
2024
Q3 		$141K Sell
13,555
-1,067
-7% -$17.7K ﹤0.01% 3393
2024
Q2 		$288K Buy
14,622
+2,961
+25% +$59.3K ﹤0.01% 3025
2024
Q1 		$299K Buy
11,661
+3,358
+40% +$86.1K ﹤0.01% 2982
2023
Q4 		$229K Sell
8,303
-15
-0.2% -$915 ﹤0.01% 3118
2023
Q3 		$506K Buy
8,318
+26
+0.3% +$1.83K ﹤0.01% 2605
2023
Q2 		$546K Buy
8,292
+79
+1% +$5.78K ﹤0.01% 2631
2023
Q1 		$522K Buy
8,213
+1,741
+27% +$199K ﹤0.01% 2414
2022
Q4 		$896K Buy
6,472
+378
+6% +$53.3K ﹤0.01% 2190
2022
Q3 		$771K Buy
6,094
+780
+15% +$88.2K ﹤0.01% 2283
2022
Q2 		$440K Buy
5,314
+822
+18% +$63.7K ﹤0.01% 2563
2022
Q1 		$436K Sell
4,492
-382
-8% -$50.4K ﹤0.01% 2482
2021
Q4 		$974K Sell
4,874
-2,731
-36% -$644K ﹤0.01% 2225
2021
Q3 		$1.88M Buy
7,605
+67
+0.9% +$19.2K ﹤0.01% 1940
2021
Q2 		$3.12M Buy
7,538
+1,994
+36% +$790K ﹤0.01% 1703
2021
Q1 		$2.17M Sell
5,544
-235
-4% -$116K ﹤0.01% 1872
2020
Q4 		$3.24M Sell
5,779
-310
-5% -$196K ﹤0.01% 1605
2020
Q3 		$4.25M Buy
6,089
+150
+3% +$117K 0.01% 1269
2020
Q2 		$4.7M Buy
5,939
+1,165
+24% +$879K 0.01% 1249
2020
Q1 		$2.84M Buy
4,774
+1,028
+27% +$1M 0.01% 1359
2019
Q4 		$4.26M Buy
3,746
+103
+3% +$112K 0.01% 1349
2019
Q3 		$4.33M Buy
3,643
+30
+0.8% +$45.8K 0.01% 1268
2019
Q2 		$5.95M Sell
3,613
-580
-14% -$1M 0.01% 1100
2019
Q1 		$8.54M Sell
4,193
-106
-2% -$187K 0.02% 850
2018
Q4 		$5.53M Sell
4,299
-56
-1% -$85.9K 0.01% 1039
2018
Q3 		$8.24M Buy
4,355
+216
+5% +$446K 0.02% 785
2018
Q2 		$8.41M Buy
4,139
+134
+3% +$305K 0.02% 766
2018
Q1 		$8.86M Sell
4,005
-123
-3% -$313K 0.02% 719
2017
Q4 		$9.52M Sell
4,128
-593
-13% -$1.2M 0.02% 713
2017
Q3 		$8.4M Buy
4,721
+623
+15% +$870K 0.02% 755
2017
Q2 		$5.58M Sell
4,098
-54
-1% -$65.2K 0.01% 939
2017
Q1 		$4.89M Buy
4,152
+365
+10% +$372K 0.01% 1012
2016
Q4 		$3.03M Buy
3,787
+127
+3% +$101K 0.01% 1202
2016
Q3 		$3.21M Buy
3,660
+155
+4% +$112K 0.01% 1127
2016
Q2 		$1.97M Buy
3,505
+775
+28% +$439K 0.01% 1358
2016
Q1 		$1.5M Sell
2,730
-38
-1% -$23.3K ﹤0.01% 1558
2015
Q4 		$2.3M Buy
2,768
+156
+6% +$156K 0.01% 1270
2015
Q3 		$2.89M Buy
2,612
+151
+6% +$275K 0.01% 1121
2015
Q2 		$5.37M Buy
2,461
+448
+22% +$913K 0.02% 802
2015
Q1 		$3.15M Buy
2,013
+598
+42% +$789K 0.01% 1104
2014
Q4 		$1.68M Buy
1,415
+112
+9% +$74.8K ﹤0.01% 1474
2014
Q3 		$605K Buy
1,303
+62
+5% +$28.6K ﹤0.01% 2090
2014
Q2 		$620K Buy
+1,241
New +$398K ﹤0.01% 2134

Other funds holding BLUE

Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RhumbLine Advisers's BLUE Position: Q2 2025 in Review

RhumbLine Advisers sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 12,522 shares — an estimated $61.1K sold.

RhumbLine Advisers first reported a position in BLUE in Q2 2014 and held it in 44 quarters. The position peaked at $9.52M in Q4 2017. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • RhumbLine Advisers reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 12,522 bluebird bio shares in Q2 2025, an estimated $61.1K.
  • RhumbLine Advisers first reported a position in bluebird bio in Q2 2014 and held it in 44 quarters.
  • RhumbLine Advisers's bluebird bio position peaked at $9.52M in Q4 2017.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.